Literature DB >> 3315789

64,000-Mr autoantigen in type I diabetes. Evidence against its surface location on human islets.

P G Colman1, I L Campbell, T W Kay, L C Harrison.   

Abstract

The sera of type I (insulin-dependent) diabetic subjects are reported to contain autoantibodies against a 64,000-Mr protein identified in [35S]methionine biosynthetically labeled pancreatic islet cells. We have attempted to localize this autoantigen to the surface of the beta-cell and to define its properties. Sera from 10 newly diagnosed type I diabetic subjects, including five of the index sera originally used to identify the autoantigen, were shown to specifically precipitate a reduced protein of 67,000 Mr from Triton-solubilized, surface 125I-labeled cultured adult human islet and rat insulinoma (RINm5F) cells but not from fresh rat spleen cells. Further characterization revealed that this protein was bovine serum albumin (BSA) adsorbed to cells from fetal calf serum (FCS)-supplemented culture medium and precipitated by BSA antibodies present in many diabetic sera. No labeled proteins were specifically precipitated when surface 125I-labeled and solubilized human islet or RINm5F cells were precleared with anti-BSA immunoglobulins or when cells were first cultured in human serum. In contrast, a 64,000-Mr protein, clearly not BSA, was precipitated by diabetic globulins from human islets but not from RINm5F cells labeled with [35S]methionine. In addition, a protein of the same size as well as proteins of approximately 35,000, 43,000, 140,000, and 200,000 Mr were specifically precipitated by diabetic globulins from freshly isolated human islets solubilized in Triton X-100 and then labeled with 125I. These findings suggest that the 64,000-Mr antigen is not expressed on the surface of human islet cells, at least in culture, and therefore question its relevance as a target for islet cell surface antibodies in initiating beta-cell damage.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3315789     DOI: 10.2337/diab.36.12.1432

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  7 in total

1.  Antibodies to a Mr-64,000 islet cell protein in Swedish children with newly diagnosed type 1 (insulin-dependent) diabetes.

Authors:  M Christie; M Landin-Olsson; G Sundkvist; G Dahlquist; A Lernmark; S Baekkeskov
Journal:  Diabetologia       Date:  1988-08       Impact factor: 10.122

Review 2.  Islet cell autoantigens in insulin-dependent diabetes.

Authors:  M A Atkinson; N K Maclaren
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

Review 3.  A model for the involvement of MHC class II proteins in the development of type 1 (insulin-dependent) diabetes mellitus in response to bovine serum albumin peptides.

Authors:  B H Robinson; H M Dosch; J M Martin; H K Akerblom; E Savilahti; M Knip; J Ilonen
Journal:  Diabetologia       Date:  1993-04       Impact factor: 10.122

4.  Monoclonal autoantibodies from insulin-dependent diabetic patients: autoantibodies against beta-cell surface or cytoplasmic antigens.

Authors:  E Houssaint; S Pogu; M Ouary; P Sai
Journal:  Clin Exp Immunol       Date:  1990-10       Impact factor: 4.330

5.  Disease-associated anti-bovine serum albumin antibodies in type 1 (insulin-dependent) diabetes mellitus are detected by particle concentration fluoroimmunoassay, and not by enzyme linked immunoassay.

Authors:  J Karjalainen; T Saukkonen; E Savilahti; H M Dosch
Journal:  Diabetologia       Date:  1992-10       Impact factor: 10.122

6.  GABA and pancreatic beta-cells: colocalization of glutamic acid decarboxylase (GAD) and GABA with synaptic-like microvesicles suggests their role in GABA storage and secretion.

Authors:  A Reetz; M Solimena; M Matteoli; F Folli; K Takei; P De Camilli
Journal:  EMBO J       Date:  1991-05       Impact factor: 11.598

Review 7.  Antibody markers in predicting type 1 diabetes: a review.

Authors:  T J Wilkin
Journal:  J R Soc Med       Date:  1990-10       Impact factor: 18.000

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.